Zonisamide and Topiramate Combination Therapy: Safety and Tolerability
Abstract number :
3.137
Submission category :
Year :
2001
Submission ID :
3081
Source :
www.aesnet.org
Presentation date :
12/1/2001 12:00:00 AM
Published date :
Dec 1, 2001, 06:00 AM
Authors :
B. Vazquez, MD, Comprehensive Epilepsy Center, NYU-Mount Sinai, New York, NY; G. Ghacibeh, MD, Comprehensive Epilepsy Center, NYU-Mount Sinai, New York, NY; M. Hopkins, RN, Comprehensive Epilepsy Center, NYU-Mount Sinai, New York, NY; O. Devinsky, MD, Com
RATIONALE: Zonisamide and topiramate are antiepilepsy drugs (AEDs) that inhibit carbonic anhydrase. Carbonic anhydrase inhibitors have been associated with an increased risk of renal calculus development in patients. The purpose of this study was to examine increased risk of kidney stones in patients receiving concomitant therapy with zonisamide and topiramate.
METHODS: Retrospective chart review was performed on 40 patients seen at NYU-Mount Sinai Comprehensive Epilepsy Center from June 2000 to May 2001, with a diagnosis of either localization-related epilepsy or generalized epilepsy. All concomitant medications were recorded, duration of treatment and prior history of kidney stones were noted. Subjects receiving zonisamide and topiramate combination therapy were identified.
RESULTS: The mean age of the patients was 24.76 years (range 6-54 years). All patients used zonisamide in combination therapy. The mean number of antiepilepsy drugs (AEDs) was 2.2. The most commonly used AEDs were levetiracetam (20 patients), oxacarbazepine (11 patients), valproic acid (10 patients), and topiramate (10 patients). There were no renal calculus reported for any of the subjects.
CONCLUSIONS: Although zonisamide and topiramate have been associated with an increased risk of renal calculus in clinical trials, and both drugs are weak carbonic anhydrase inhibitors, we have been able to use these two drugs in combination therapy without any occurrence of renal calculus.
Support: Elan Pharmaceuticals